Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Type 2 diabetes: Complications and comorbidities

Journal articles and book chapters

07-03-2018 | Type 2 diabetes | Article

Adiposity-mortality relationships in type 2 diabetes, coronary heart disease, and cancer subgroups in the UK Biobank, and their modification by smoking

Jenkins DA et al. Diabetes Care 2018. doi: 10.2337/dc17-2508

07-03-2018 | Hypoglycemia | Article

Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes

Lipska KJ et al. JAMA 2018; 320: 53–62. doi: 10.1001/jama.2018.7993

06-30-2018 | Insulin NPH | Article

Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine Hagedorn insulin protocol: A randomized clinical trial

Khowaja A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0468-3

06-30-2018 | Metformin | Review | Article

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

06-27-2018 | Metformin | Article

Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan

Matsuura N et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0361-3

06-27-2018 | Hyperglycemia | Article

Contribution of BHG and PPHG to overall hyperglycemia in T2DM patients treated with LM25 and LM50: Post hoc analysis of a randomized crossover trial

Li W et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0462-9

06-26-2018 | Diabetic foot | Article

Community based study to assess the prevalence of diabetic foot syndrome and associated risk factors among people with diabetes mellitus

Vibha SP et al. BMC Endocr Disord 2018; 18: 43. doi: 10.1186/s12902-018-0270-2

06-26-2018 | Diabetes distress | Article

High diabetes distress among ethnic minorities is not explained by metabolic, cardiovascular, or lifestyle factors: Findings from the Dutch diabetes pearl cohort

Özcan B et al. Diabetes Care 2018. doi: 10.2337/dc17-2181

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

06-23-2018 | Heart failure | Article

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: A real-world nationwide population-based cohort study

Kim YG et al. Cardiovasc Diabetol 2018; 17: 91. doi: 10.1186/s12933-018-0737-5

06-23-2018 | Devices and technology | Review | Article

Diabetes technology update: Use of insulin pumps and continuous glucose monitoring in the hospital

Umpierrez GE, Klonoff DC. Diabetes Care 2018. doi: 10.2337/dci18-0002

06-22-2018 | Hypertension | Review | Article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

06-22-2018 | Monogenic diabetes | Review | Article

Advances in the genetics of youth-onset type 2 diabetes

Todd JN, Srinivasan S, Pollin TI. Curr Diab Rep 2018; 18: 57. doi: 10.1007/s11892-018-1025-1

06-22-2018 | Gastroparesis | Review | Article

Diabetic gastroparesis: Principles and current trends in management

Krishnasamy S, Abell TL. Diabetes Ther (2018); 9 (Suppl 1): 1. doi: 10.1007/s13300-018-0454-9

06-21-2018 | Genetics | Review | Article

Impact of genetic determinants of HbA1c on type 2 diabetes risk and diagnosis

Sarnowski C, Hivert MF. Curr Diab Rep 2018; 18: 52. doi: 10.1007/s11892-018-1022-4

06-21-2018 | Pathophysiology | Review | Article

The gut microbiome as a target for the treatment of type 2 diabetes

Aydin Ö, Nieuwdorp M, Gerdes V. Curr Diab Rep 2018; 18: 55. doi: 10.1007/s11892-018-1020-6

06-21-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

06-21-2018 | Sleep disorders | Article

Relationship between sleep disturbance and self-care in adults with type 2 diabetes

Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4

06-20-2018 | Ipragliflozin | Article

Ipragliflozin add-on therapy to a GLP-1 receptor agonist in Japanese patients with type 2 diabetes (AGATE): A 52-week open-label study

Ishihara H et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0455-8

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

Next Previous